ReviewVaccines2020
Management of the Adverse Effects of Immune Checkpoint Inhibitors.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 52 citations in OpenAlex.
- Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Chronic diseases and translational medicine · 2026Review
- Immune Checkpoint Inhibitor-Induced Vogt-Koyanagi-Harada-like Disease Complicated by Inflammatory Macular Neovascularisation: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Tislelizumab-induced Vogt-Koyanagi-Harada-like uveitis: a case report.BMC ophthalmology · 2026Article
- Review
- Past present and future of radiosensitization in cervical cancer.Frontiers in oncology · 2026Review
- Effectiveness of Atezolizumab in Addition to Chemotherapy in ES-SCLC: A Retrospective Real-World Monocentric Study.Cancers · 2025Article
- Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician.The Journal of clinical and aesthetic dermatology · 2025Review
- Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series.Eye (London, England) · 2025Article
- Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis.Biological procedures online · 2025Article
- Managing Advanced Basal Cell Carcinoma: A Guide for the Dermatology Clinician.The Journal of clinical and aesthetic dermatology · 2025Review
- Immune surveillance as a pharmacological target in the early stages of cancer.Frontiers in molecular biosciences · 2025Article
- Tumor necrosis factor superfamily signaling: life and death in cancer.Cancer metastasis reviews · 2024Review
- PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy.Drug delivery and translational research · 2024Article
- Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).Experimental and therapeutic medicine · 2024Review
- Review
- Lipid-based nanosystems: the next generation of cancer immune therapy.Journal of hematology & oncology · 2024Review
- A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers.International journal of molecular sciences · 2024Review
- Immune checkpoint inhibitors in high-grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation.BJUI compass · 2024Article
- Pembrolizumab-Associated Unilateral Optic Neuritis.Journal of clinical neurology (Seoul, Korea) · 2024Article
- Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By increasing the activity of the immune system, immune checkpoint inhibitors (ICPI) can have adverse inflammatory effects, which are referred to as immune-related adverse effects (irAEs). In this review, we present the recommendations for the appropriate identification and treatment of irAEs associated with ICPI to increase the safety and effectiveness of therapy with these immuno-oncological drugs. Several guidelines to manage irAEs adopted by different American and European societies in the field of oncology were identified. A narrative review of the several strategies adopted to manage irAEs was performed. With close clinical surveillance, ICPI can be used even in patients who have mild irAEs. Moderate to severe events require early detection and appropriate treatment, particularly in patients with a history of transplantation or pre-existing autoimmune disease. In most cases, adverse reactions can be treated with the interruption of treatment and/or supportive therapy, which includes, in serious adverse reactions, the administration of immunosuppressants. The identification and treatment of irAEs in the early stages may allow patients to resume therapy with ICPI. This review is an instrument to support healthcare professionals involved in the treatment and monitoring of patients who are administered ICPI, contributing to the timely identification and management of irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.